Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

Abstract Background In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget imp...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Hyun Kyeong Yoo, Han Geul Byun, Flavio Caprioli, Mathurin Fumery, Laurent Peyrin-Biroulet, Subramanian Sreedhar, James Potter, Minyoung Jang
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	BMC 2022-11-01
Cyfres:	BMC Health Services Research
Pynciau:	Inflammatory bowel disease Ulcerative colitis Crohn’s disease Budget impact
Mynediad Ar-lein:	https://doi.org/10.1186/s12913-022-08683-y
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!